Enzyme replacement therapy for lysosomal storage disorders;Le traitement par enzymothérapie des maladies lysosomales

Archives de Pediatrie

Volumn 18, Issue 10, 2011, Pages 1119-1123

  Valayannopoulos, V ^a   Brassier, A ^a   Chabli, A ^a   Caillaud, C ^a   Lemoine, M ^a   Odent, T ^a   Arnoux, J B ^a   de Lonlay, P ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENZYME REPLACEMENT; HUMAN; LYSOSOME STORAGE DISEASE;

CLINICAL TRIALS AS TOPIC; ENZYME REPLACEMENT THERAPY; ENZYMES; FABRY DISEASE; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; LYSOSOMAL STORAGE DISEASES; MUCOPOLYSACCHARIDOSES; TREATMENT OUTCOME;

EID: 80053340439     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/j.arcped.2011.07.002     Document Type: Article

References (23)

1. Parkinson-Lawrence E.J., Shandala T., Prodoehl M., et al. Lysosomal storage disease: revealing lysosomal function and physiology. Physiology (Bethesda) 2010, 25:102-115.
2. Bellettato C.M., Scarpa M. Pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis 2010, 33:347-362.
3. Kim S.U., de Vellis J. Stem cell-based cell therapy in neurological diseases: a review. J Neurosci Res 2009, 87:2183-2200.
4. Fratantoni J.C., Hall C.W., Neufeld E.F. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968, 162:570-572.
5. Barton N.W., Brady R.O., Dambrosia J.M., et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991, 324:1464-1470.
6. Weinreb N.J. Imiglucerase and its use for the treatment of Gaucher's disease. Expert Opin Pharmacother 2008, 9:1987-2000.
7. Davies E.H., Erikson A., Collin-Histed T., et al. Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases. J Inherit Metab Dis 2007, 30:935-942.
8. Prows C.A., Sanchez N., Daugherty C., et al. Gaucher disease: enzyme therapy in the acute neuronopathic variant. Am J Med Genet 1997, 71:16-21.
9. Cox T.M. Gaucher disease: clinical profile and therapeutic developments. Biologics 2010, 4:299-313.
10. Hoffmann B. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis 2009, 4:21.
11. Beck M. Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety. Expert Opin Biol Ther 2009, 9:255-261.
12. Lidove O., West M.L., Pintos-Morell G., et al. Effects of enzyme replacement therapy in Fabry disease: a comprehensive review of the medical literature. Genet Med 2010, 12:668-679.
13. Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr 2004, 144:S27-S34.
14. Clarke L.A., Wraith J.E., Beck M., et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009, 123:229-240.
15. Harmatz P., Giugliani R., Schwartz I.V., et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 2008, 94:469-475.
16. Wraith J.E., Scarpa M., Beck M., et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008, 167:267-277.
17. Bembi B., Cerini E., Danesino C., et al. Diagnosis of glycogenosis type II. Neurology 2008, 71:S4-S11.
18. Nicolino M., Byrne B., Wraith J.E., et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 2009, 11:210-219.
19. van der Ploeg A.T., Clemens P.R., Corzo D., et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010, 362:1396-1406.
20. Brooks D.A., Kakavanos R., Hopwood J.J. Significance of immune response to enzyme replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med 2003, 9:450-453.
21. Kakavanos R., Turner C.T., Hopwood J.J., et al. Immune tolerance after long-term enzyme replacement therapy among patients who have mucopolysaccharidosis I. Lancet 2003, 361:1608-1613.
22. Sun B., Bird A., Young S.P., et al. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet 2007, 81:1042-1049.
23. Cox-Brinkman J., Boelens J.J., Wraith J.E., et al. Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant 2006, 38:17-21.